Clinical trials: Schizophrenia, Schizoaffective Disorder
Schizophrenia, Schizophreniform Disorder
An Efficacy and Safety Study of Risperidone Long-Acting Microspheres in Participants With Schizophrenia, Schizophreniform or Schizoaffective Disorders
The purpose of this study is to evaluate the efficacy and safety of long acting injectable microspheres of risperidone in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment…
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder
- Trial name
- NCT01855074
- Testing
- Risperidone
- Volunteers
- 80 people
- Sponsor
- Janssen-Cilag Ltd.
Schizophrenia
Digoxin Drug-Drug Interaction With Lurasidone HCl
The objective of this study is to evaluate the pharmacokinetic profile of digoxin when administered alone and when administered with repeated dose of lurasidone 120mg.
- Trial name
- NCT01082289
- Testing
- Lurasidone
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia or Schizoaffective Disorder
Multiple Ascending Dose Study on Safety, Tolerability, and Pharmacokinetics of AMG 581 in Healthy Subjects or Subjects With Schizophrenia or Schizoaffective
The purpose of this study is to find out the time it takes to absorb, distribute, breakdown and remove the drug from the body in healthy participants and subjects with schizophrenia and whether it causes any side effects.
- Trial name
- MAD (NCT02504476)
- Testing
- AMG 581, Midazolam
- Where
- 2 sites in United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Amgen
Schizophrenia, Schizoaffective Disorder
As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations
The purpose of this study is to compare the steady-state pharmacokinetics of paliperidone after oral administration of 15 mg extended-release (ER) OROS paliperidone once daily with the steady-state pharmacokinetics of…
- Trial name
- NCT00796185
- Testing
- Paliperidone ER
- Volunteers
- 62 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Psychotic Disorders
A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)
The purpose of the study is to evaluate the maintained effectiveness of long-acting injectable risperidone (RISPERDAL® CONSTA™) compared with the previous treatment with oral olanzapine in non-acute subjects with schizophrenia or…
- Trial name
- NCT00216632
- Testing
- risperidone
- Volunteers
- 99 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia, Schizoaffective Disorder
Observational Study to Evaluate Bipolar Disorder Symptoms in Patients Presented With Schizophrenia or Depression
This study is aimed to evaluate the bipolar disorder symptoms in patients presented with schizophrenia, schizoaffective disorder or recurrent depression.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Recurrent Depression
- Trial name
- NCT01028196
- Where
- 3 sites in Russia
- Volunteers
- 750 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorder
A Long Term Study of Safety for Long Acting Injectable Risperidone in Patients With Schizophrenia or Schizoaffective Disorder.
The purpose of this study is to document the long-term safety of 25, 50 or 75 mg long-acting injectable risperidone given via injection to the gluteal muscle every 2 weeks to patients with schizophrenia or schizoaffective…
- Trial name
- NCT00558298
- Testing
- risperidone
- Volunteers
- 811 people
- Sponsor
- Janssen, LP
Tardive Dyskinesia
Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
The primary objective is to assess the safety and effectiveness of Pyridoxal 5'-Phosphate on the reduction of expressed symptoms of tardive dyskinesia in patients with schizophrenia and schizoaffective disorders.
- Trial name
- NCT00917293
- Testing
- Pyridoxal 5'-Phosphate
- Where
- 4 sites in Canada, India
- Volunteers
- 53 people
- Sponsor
- Medicure
Body Weight Change, Schizophrenia
Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
The primary purpose of this study is to compare the affects of aripiprazole and olanzapine on weight change.
- Conditions
- Body Weight Change, Schizophrenia, Schizoaffective Disorder, Psychotic Disorder
- Trial name
- NCT00095524
- Testing
- Aripiprazole
- Where
- 32 sites in United States, Brazil and 1 more
- Volunteers
- 300 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia, Schizoaffective Disorder
Seroquel Long-Term NIS for Schizophrenia Patients
To assess the efficacy of 24-week treatment with quetiapine in patients with schizophrenia or schizoaffective disorder
- Trial name
- SELECT (NCT00523783)
- Where
- 3 sites in South Korea
- Volunteers
- 1,000 people
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorder
A Study of QT and QTc Intervals in Patients Administered Extended Release Paliperidone or Quetiapine
The purpose of this study is to 1) determine whether the effect on QT interval corrected (QTcLD) for heart rate using the population specified linear derived method at steady state is comparable between 12 mg paliperidone…
- Trial name
- NCT00791622
- Testing
- Paliperidone ER
- Volunteers
- 110 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Psychotic Disorders
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
This is a randomized, single-dose, open-label, parallel-group study. Patients will undergo the screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT05321602
- Testing
- LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid
- Where
- 9 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenic Disorders, Schizoaffective Disorder
Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder
This is a long-term, open-label clinical study designed to enable longer-term treatment of patients completing other clinical studies with intramuscular olanzapine depot.
- Trial name
- NCT00088465
- Testing
- Intramuscular olanzapine depot
- Where
- 92 sites in United States, Argentina and 23 more
- Volunteers
- 931 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Schizo-affective Disorder
Study in Stabilized Schizophrenic Patients to Evaluate the Pharmacokinetics of Risperidone and 9-Hydroxy (OH)-Risperidone When Risperidone is Administered From a Polyurethane Implant
The study will be a 6-month, open-label, multiple center study in approximately 50 stable subjects diagnosed with schizophrenia or schizoaffective disorder to evaluate the safety, tolerability, and pharmacokinetics of Risperidone…
- Trial name
- NCT02658357
- Testing
- Risperidone Implant
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Braeburn Pharmaceuticals
Schizoaffective Disorder, Schizophrenia
A Study Comparing Three Strategies to Switch Patients With Schizophrenia or Schizoaffective Disorder to Risperidone After Unsuccessful Treatment With Olanzapine.
The purpose of this study is to compare three strategies for switching patients with schizophrenia or schizoaffective disorder to the atypical antipsychotic, risperdone, after they have been unsuccessfully treated with another…
- Trial name
- NCT00378183
- Testing
- risperidone
- Volunteers
- 120 people
- Sponsor
- Janssen, LP
Schizophrenia, Schizo-Affective Disorder
Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
This is a study of the efficacy and safety of BXCL501 in children and adolescents with acute agitation and either bipolar disorder or schizophrenia.
- Conditions
- Schizophrenia, Schizo-Affective Disorder, Schizophreniform; Schizophrenic, Bipolar Disorder I
- Trial name
- NCT05025605
- Testing
- BXCL501 80 Micrograms, BXCL501 120 Micrograms, BXCL501 60 Micrograms
- Where
- 5 sites in United States
- Volunteers
- 140 people
- Sponsor
- BioXcel Therapeutics Inc
Schizophrenia, Bipolar Disorder
A Drug Interaction Study of Valproic Acid and Paliperidone Extended-Release (ER) in Patients With Schizophrenia, Bipolar I Disorder, or Schizoaffective Disorder
The purpose of this study is to evaluate the potential effect of multiple oral doses of an extended release formulation of paliperidone on the pharmacokinetics (blood levels) of valproic acid (VPA) in patients with schizophrenia…
- Conditions
- Schizophrenia, Bipolar Disorder, Psychotic Disorders
- Trial name
- NCT01094249
- Testing
- divalproex sodium ER/paliperidone ER
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Schizophrenia, Schizoaffective Disorder
POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia
This Phase I/IIa Proof-of-Concept (PoC) trial is designed to assess the effect of adding a single and repeated low dose (15mg/d) of pipamperone (PIP) for 6 weeks to stable treatment with an effective dose of risperidone (RIS) or…
- Trial name
- NCT01450514
- Testing
- Pipamperone
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- PharmaNeuroBoost N.V.
Schizophrenia, Schizoaffective Disorder
Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to characterize the pharmacokinetics (PK) of LY03004 following an escalating single intramuscular injection at 12.5, 25, 37.5, or 50 mg; and to evaluate the safety and tolerability and preliminary…
- Trial name
- LY03004SAD (NCT02055287)
- Testing
- LY03004
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia, Schizoaffective Disorder
Health Evaluation of Abilify Long-term Therapy
This is a post-market surveillance, and the treatment to patients will be depended upon the decision based on physician's clinical judgment.
- Trial name
- HEALTH (NCT00520650)
- Testing
- Aripiprazole
- Where
- 9 sites in Taiwan
- Volunteers
- 245 people
- Sponsor
- Taiwan Otsuka Pharm. Co., Ltd